TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04526964

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management curriculum
Description: The Intervention starts during inpatient phase after relocation of potential study participants from the intensive care unit to normal ward and after informed consent to participate. Those subjects assigned to the CGr by randomization code receive standard care at the respective center. Subjects assigned to the IGr received, in addition to standard care, a multi-modular self-management training carried out at the respective center. The content of the self-management training should be deepened and consolidated through a supplementary app. Training is performed during inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up. The intervention lasts 3 months, plus a 9-month follow-up per subject. The content of the self-management training is based on current evidence and was written in a curriculum to achieve the highest possible standardization, taking into account the center specifics.
Study: NCT01450085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GeneXpert
Description: Point of care GeneXpert

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LED Microscopy
Description: Point of care LED Microscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LED Microscopy
Description: Point of care LED Microscopy
Study: NCT03011684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: For ER Positive Randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: For ER Positive Randomization
Study: NCT03077516

Intervention type: DEVICE
Intervention: Mobi-C
Description: Device for cervical intervertebral disc replacement at one or two contiguous levels
Study: NCT04213690

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT00679965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 2.5%
Description: Once daily application for 90 days and 3 x weekly for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 5%
Description: Once daily application for 90 days and 3 x weekly for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 7.5%
Description: Once daily application for 90 days and 3 x weekly for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2690 Solution Vehicle
Description: Once daily application for 90 days and 3x weekly for 90 days
Study: NCT03255421

Intervention type: OTHER
Intervention: Pressure measurement
Description: Observational study No intervention, only fragmenting the emptying of the bladder
Study: NCT00813293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: radiofrequency ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study: NCT01682083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
Study: NCT02544594

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-Corporal Life Support (ECLS)
Description: Extra-Corporal Life Support (ECLS) (from Sorin)
Study: NCT00860405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)
Description: Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human serum albumin (HSA 50g/L)
Description: Human serum albumin (HSA 50g/L)
Study: NCT01728922

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 5000IU vitamin D
Description: Vigantol Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 5000IU vitamin D
Description: Vigantol Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10000IU vitamin D
Description: Vigantol Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10000IU vitamin D
Description: Vigantol Oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oil
Study: NCT04406441

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Reported Outcome Well Child Visit
Description: Parents will complete the Family Nutrition and Physical Activity risk assessment (Patient Reported Outcome) prior to scheduled well child visit. Parent reported data is integrated into the child's electronic health record to inform the child's primary care provider and the provision of preventive counseling. The primary care provider documents preventive care provided.
Study: NCT05176132

Intervention type: OTHER
Intervention: No intervention
Description: Control groups (BMI 20-25 and BMI 25-30)
Study: NCT04473417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration after 10hr fasting
Study: NCT04406441

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Reported Outcome Well Child Visit + Food Care
Description: Adapted Parent Training Program will be delivered via telehealth (video or telephone) to parents by trained Wellness Coaches as 6 individual sessions, distributed throughout a 26-week intervention period. Cooking Matters grocery store tours will be delivered (in-person or virtual) to parents by trained grocery store nutritionists during the 26-week intervention period.
Study: NCT03559023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Only
Description: The anesthesia team will use ultrasound to scan on subject's upper back (thoracic spine) to identify a place to begin the epidural procedure. A pen will be used to place markings on subject's back.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manometry Only
Description: The anesthesia team will use an extra piece of tubing to confirm the epidural space one the epidural space is established.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Plus Manometry
Description: The anesthesia team will use both ultrasound and manometry to assist with epidural placement.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Usual Care/Management
Description: The epidural will be placed using the usual technique utilized by the anesthesiology department. The the usual care/management group will receive a sham (fake) ultrasound exam of subject's upper back with fake pen markings placed on subject's back. The ultrasound machine will not be turned on.
Study: NCT01563965

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate plus hydrolyzed protein beverage
Description: The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative fasting of 8h
Description: Conventional protocol of 8h fasting before an operation
Study: NCT02987491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
Study: NCT01895205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Study: NCT03195374

Intervention type: OTHER
Intervention: Prescription Opioid Misus Index
Description: Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
Study: NCT02379247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL-719 (alpelisib)
Description: Oral PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL-719 (alpelisib)
Description: Oral PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL-719 (alpelisib)
Description: Oral PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL-719 (alpelisib)
Description: Oral PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV taxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV taxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV taxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV taxane
Study: NCT03037372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART, Atorvastatin
Description: ART, Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART, Rosuvastatin
Description: ART, Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART, No statin
Description: ART, No statin
Study: NCT04473417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration after 10hr fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration after 10hr fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration after 10hr fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration after high fat and calorie fed diet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2811
Description: single dose administration after high fat and calorie fed diet
Study: NCT02492438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV23 vaccination or PCV13 vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV23 vaccination or PCV13 vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV23 vaccination or PCV13 vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23 vaccination or PCV13 vaccination
Study: NCT00744445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-HuEPO
Description: r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-HuEPO
Description: r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-HuEPO
Description: r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
Study: NCT02734069

Intervention type: DRUG
Intervention: Carboplatin
Description: Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.

Intervention type: DRUG
Intervention: Carboplatin
Description: Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
Study: NCT04484532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Given IM
Study: NCT03037372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Healthy-HIV-negative
Description: Age-matched, Healthy HIV-negative
Study: NCT01190163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT02351154

Intervention type: OTHER
Group type: OTHER
Intervention: Cellvizio Viewer software
Description: permets to perform analysis of diameters in micrometers
Study: NCT02598479

Intervention type: OTHER
Intervention: IPTLD and nutrition therapy
Description: The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
Study: NCT03206866

Intervention type: DIAGNOSTIC_TEST
Intervention: serum regucalcin antibody
Description: serum regucalcin antibody

Intervention type: DIAGNOSTIC_TEST
Intervention: serum regucalcin antibody
Description: serum regucalcin antibody

Intervention type: DIAGNOSTIC_TEST
Intervention: serum regucalcin antibody
Description: serum regucalcin antibody
Study: NCT03971825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92252
Description: CC-92252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92252
Description: CC-92252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02724800

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTI
Description: 28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BBTI
Description: 28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
Study: NCT03095846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Individualized cooling protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Individualized cooling protocol
Study: NCT00952406

Intervention type: OTHER
Intervention: Survey
Description: This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
Study: NCT03139019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process incentives
Description: Participants will receive cash based incentives for achieving process based measures (class attendance).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outcome incentives
Description: Participants will receive cash based incentives for outcome based measures (weight loss).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process and Outcome incentives
Description: Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
Study: NCT00389064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
Study: NCT00376922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: music therapy
Description: music played for patient during bone marrow biopsy collection
Study: NCT02869425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen ER Tablets
Description: arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for arbaclofen ER tablets
Description: matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
Study: NCT01631422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Single radiolabeled dose
Study: NCT00907998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL180

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00784823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m2
Description: * Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2
Description: * Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m2
Description: * Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m2
Description: * Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen
Study: NCT05182346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: * Acupressure of acupoints is manipulation of classic acupoints by pressure.~* Ischemic compression release is applying pressure to the myofascial trigger points until release of these points.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: * Acupressure of acupoints is manipulation of classic acupoints by pressure.~* Ischemic compression release is applying pressure to the myofascial trigger points until release of these points.
Study: NCT00784823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: * Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: * Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: * Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: * Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight
Study: NCT03855332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: See above

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: See above

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Overencapsulated placebo
Study: NCT00863746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 2 tablets twice daily (BID)
Study: NCT02096510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Cortef
Description: administration by pump for minimum 2 weeks